HOUSE 2374116th CongressPlaced on the Union Calendar, Calendar No. 577.
Stop STALLING Act
- Last Action
- 12/24/2020
Actions
- 2020-12-24Placed on the Union Calendar, Calendar No. 577.
- 2020-12-24Reported by the Committee on Judiciary. H. Rept. 116-694.
- 2020-12-24Reported by the Committee on Judiciary. H. Rept. 116-694.
- 2019-04-30Ordered to be Reported by Voice Vote.
- 2019-04-30Committee Consideration and Mark-up Session Held.
- 2019-04-29Referred to the House Committee on the Judiciary.
- 2019-04-29Introduced in House
- 2019-04-29Introduced in House
CRS Summary
As of 2020-12-24 (07)
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Cosponsors (7)
- F. SENSENBRENNER (R-WI)
- JERROLD NADLER (D-NY)
- Doug Collins (R-GA)
- David Cicilline (D-RI)
- Peter Welch (D-VT)
- Steve Cohen (D-TN)
- Bill Posey (R-FL)
Subjects
- Administrative law and regulatory procedures
- Business ethics
- Civil actions and liability
- Competition and antitrust
- Drug safety, medical device, and laboratory regulation
- Federal Trade Commission (FTC)
- Licensing and registrations
- Public participation and lobbying
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.